blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1688036

EP1688036 - TRANSGENIC NONHUMAN MAMMAL [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  19.04.2013
Database last updated on 20.05.2024
Most recent event   Tooltip19.04.2013Application deemed to be withdrawnpublished on 22.05.2013  [2013/21]
Applicant(s)For all designated states
TAISHO PHARMACEUTICAL CO., LTD
24-1 Takata 3-chome, Toshima-ku
Tokyo 170-8633 / JP
[2006/32]
Inventor(s)01 / YOSHIMOTO, Makoto
c/o Taisho Pharmaceutical Co., Ltd.
24-1, Takada 3-chome
Toshima-ku
Tokyo 1708633 / JP
02 / WAKAMATSU, Masaki
c/o Taisho Pharmaceutical Co., Ltd.
24-1, Takada 3-chome
Toshima-ku
Tokyo 1708633 / JP
03 / ISHII, Aiko
c/o Taisho Pharmaceutical Co., Ltd.
24-1, Takada 3-chome
Toshima-ku
Tokyo 1708633 / JP
 [2012/32]
Former [2006/32]01 / YOSHIMOTO, Makoto, Taisho Pharmaceutical Co., Ltd.
24-1, Takada 3-chome, Toshima-ku
Tokyo 1708633 / JP
02 / WAKAMATSU, Masaki, Taisho Pharmaceutical Co., Ltd.
24-1, Takada 3-chome, Toshima-ku
Tokyo 1708633 / JP
03 / ISHII, Aiko, c/o Taisho Pharmaceutical Co., Ltd.
24-1, Takada 3-chome, Toshima-ku
Tokyo 1708633 / JP
Representative(s)polypatent
An den Gärten 7
51491 Overath / DE
[N/P]
Former [2012/02]Polypatent
An den Gärten 7
51491 Overath / DE
Former [2010/01]Polypatent
Postfach 40 02 43
51410 Bergisch Gladbach / DE
Former [2006/32]Sternagel, Fleischer, Godemeyer & Partner
Patentanwälte, An den Gärten 7
51491 Overath / DE
Application number, filing date04793353.628.10.2004
[2006/32]
WO2004JP16373
Priority number, dateJP2003037050730.10.2003         Original published format: JP 2003370507
JP2004008263722.03.2004         Original published format: JP 2004082637
[2006/32]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2005041649
Date:12.05.2005
Language:EN
[2005/19]
Type: A1 Application with search report 
No.:EP1688036
Date:09.08.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 12.05.2005 takes the place of the publication of the European patent application.
[2006/32]
Search report(s)International search report - published on:JP12.05.2005
(Supplementary) European search report - dispatched on:EP05.08.2009
ClassificationIPC:A01K67/027, A61K45/00, A61P25/16, C12N5/16, C12Q1/02, G01N33/15, G01N33/50, C12N15/12, C12N9/02, C12N15/85
[2009/32]
CPC:
A01K67/0275 (EP,US); A61P25/16 (EP); A61P43/00 (EP);
C07K14/47 (EP,US); C12N15/8509 (EP,US); C12N9/0073 (EP,US);
A01K2217/052 (EP,US); A01K2227/105 (EP,US); A01K2267/0318 (EP,US);
C12N2830/008 (EP,US); G01N2500/00 (EP,US) (-)
Former IPC [2006/32]A01K67/027, A61K45/00, A61P25/16, C12N5/16, C12Q1/02, G01N33/15, G01N33/50, C12N15/12
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/32]
Extension statesAL06.05.2006
HR06.05.2006
LT06.05.2006
LV06.05.2006
MK06.05.2006
TitleGerman:TRANSGENES NICHTHUMANES SÄUGETIER[2006/32]
English:TRANSGENIC NONHUMAN MAMMAL[2006/32]
French:MAMMIFERE NON HUMAIN TRANSGENIQUE[2006/32]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase06.05.2006Translation filed 
06.05.2006National basic fee paid 
06.05.2006Search fee paid 
06.05.2006Designation fee(s) paid 
06.05.2006Examination fee paid 
Examination procedure06.05.2006Examination requested  [2006/32]
16.10.2009Despatch of a communication from the examining division (Time limit: M04)
23.02.2010Reply to a communication from the examining division
06.04.2011Despatch of a communication from the examining division (Time limit: M04)
29.07.2011Reply to a communication from the examining division
11.07.2012Communication of intention to grant the patent
22.11.2012Application deemed to be withdrawn, date of legal effect  [2013/21]
08.01.2013Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2013/21]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.10.2009
Fees paidRenewal fee
12.10.2006Renewal fee patent year 03
12.10.2007Renewal fee patent year 04
31.03.2008Renewal fee patent year 05
13.10.2009Renewal fee patent year 06
12.10.2010Renewal fee patent year 07
11.10.2011Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.10.201209   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[E]WO2005013889  (ELAN PHARM INC [US], et al) [E] 1-5,7-13* paragraphs [0010] , [0012]; claims 20,25,40 *;
 [X]  - WEST N C ET AL, "EFFECTS OF MPTP ON DOPAMINERGIC NEURONS IN alpha - SYNUCLEIN TRANSGENIC MICE.", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (2002), Database accession no. PREV200300325631, XP002534069 [X] 1-3,5,7,8,11 * abstract *
    [ ] - SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002, (2002), vol. 2002, page ABSTRACT NO. 689.16
International search[A]WO9859050  (US HEALTH [US], et al);
 [A]WO0160794  (UNIV CALIFORNIA [US], et al);
 [A]US2002111321  (KLEIN RONALD [US], et al);
 [A]JP2003199460  (SHOJI MIKIO, et al);
 [A]  - MATSUOKA, Y. ET AL., "Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter", NEUROBIOL.DIS., (2001), vol. 8, no. 3, pages 535 - 539, XP002983610

DOI:   http://dx.doi.org/10.1006/nbdi.2001.0392
 [A]  - VAN DER PUTTEN, H. ET AL., "Neuropathology in mice expressing human alpha-synuclein", J.NEUROSCI., (2000), vol. 20, no. 16, pages 6021 - 6029, XP002983611

DOI:   http://dx.doi.org/10.1523/JNEUROSCI.20-16-06021.2000
 [A]  - MASLIAH, E. ET AL., "Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders", SCIENCE, (2000), vol. 287, no. 5456, pages 1265 - 1269, XP002201745

DOI:   http://dx.doi.org/10.1126/science.287.5456.1265
 [A]  - RICHFIELD, E.K. ET AL., "Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice", EXP.NEUROL, (2002), vol. 175, no. 1, pages 35 - 48, XP002983612

DOI:   http://dx.doi.org/10.1006/exnr.2002.7882
 [A]  - KIRIK, D. ET AL., "Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's DISEASE", PROC.NATL.ACAD.SCI. U.S.A., (200303), vol. 100, no. 5, pages 2884 - 2889, XP002983613

DOI:   http://dx.doi.org/10.1073/pnas.0536383100
    [ ] - LO BIANCO, C. ET AL., "alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease", PROC.NATL.ACAD.SCI. U.S.A., (2002), vol. 99, no. 16, pages 10813 - 10818, XP002983614

DOI:   http://dx.doi.org/10.1073/pnas.152339799
 [A]  - ZHOU, W. ET AL., "Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture", BRAIN RES., (2002), vol. 926, no. 1-2, pages 42 - 50, XP002983615

DOI:   http://dx.doi.org/10.1016/S0006-8993(01)03292-9
 [A]  - KANDA, S. ET AL., "Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation", NEUROSCIENCE, (2000), vol. 97, no. 2, pages 279 - 284, XP002306402

DOI:   http://dx.doi.org/10.1016/S0306-4522(00)00077-4
 [A]  - PARK, S.M. ET AL., "Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of alpha-synuclein, a molecular chaperone", J.BIOL.CHEM., (2002), vol. 277, no. 32, pages 28512 - 28520, XP002983616

DOI:   http://dx.doi.org/10.1074/jbc.M111971200
 [A]  - KIM, T.D. ET AL., "Structural and functional implications of C-terminal regions of alpha-synuclein", BIOCHEMISTRY, (2002), vol. 41, no. 46, pages 13782 - 13790, XP002983617

DOI:   http://dx.doi.org/10.1021/bi026284c
 [XP]  - ISHI, A. ET AL., "Generation and analysis of transgenic mice that express human alpha-synuclein in dopamine neurons", (20040810), vol. 43, no. 2,3, pages 369 - 0G1-06, XP002983618
 [T]  - FERNAGUT, P.O. ET AL., "Alpha-synuclein and transgenic mouse models", NEUROBIOL.DIS., (200411), vol. 17, no. 2, pages 123 - 130, XP004592551

DOI:   http://dx.doi.org/10.1016/j.nbd.2004.07.001
Examination   - WAKABAYASHI K ET AL, "NACP, A PRESYNAPTIC PROTEIN, IMMUNOREACTIVITY IN LEWY BODIES IN PARKINSON'S DISEASE", NEUROSCIENCE LETTERS, LIMERICK, IE, (19970101), vol. 239, doi:10.1016/S0304-3940(97)00891-4, ISSN 0304-3940, pages 45 - 48, XP002921163

DOI:   http://dx.doi.org/10.1016/S0304-3940(97)00891-4
    - SERPELL LOUISE C ET AL, "Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (20000425), vol. 97, no. 9, ISSN 0027-8424, pages 4897 - 4902
    - MURRAY IAN V J ET AL, "Role of alpha-synuclein carboxy-terminus on fibril formation in vitro", 20030722, (20030722), vol. 42, no. 28, pages 8530 - 8540, XP002265311
    - TOFARIS GEORGE K ET AL, "Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein (1-120): Implications for Lewy body disorders", JOURNAL OF NEUROSCIENCE, (200604), vol. 26, no. 15, ISSN 0270-6474, pages 3942 - 3950
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.